This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on AstraZeneca, with a price target of £160.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Vosser is a 3-star analyst with an average return of 1.5% and a 48.13% success rate.
Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of p16,446.19.
Based on AstraZeneca’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p15.5 billion and a net profit of p2.33 billion. In comparison, last year the company earned a revenue of p14.54 billion and had a net profit of p1.46 billion
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca’s Ultomiris Hits Phase III Mark in Rare Kidney Disease
- AstraZeneca says tozorakimab met primary endpoint in Phase III MIRANDA trial
- AstraZeneca announces tozorakimab met primary endpoint in Phase III trial
- AstraZeneca’s Tozorakimab Delivers Third Positive Phase III Result in COPD
- AstraZeneca Expands Real‑World Evidence for Acalabrutinib in CLL
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
